Our Team
Established in 2022 in Vienna, Austria by visionary scientists, VERDI Solutions is at the forefront of creating personalized cancer vaccines, utilizing peptide technology and individual patients' tumor and HLA data to advance cancer treatment.
Dr. Julianna Lisziewicz
Chief Executive Officer and Founder
Dr. Lisziewicz founded three US companies Genetic Immunity, Inc., TREOS Bio Ltd (previously eMMUNITY Inc.) and Research Institute for Genetic and Human Therapy (RIGHT) to develop innovative vaccines that enable the human immune systems to conquer some of the deadliest diseases, including HIV and cancer.
Dr. Franco Lori
Chief Medical Officer
Dr. Lori has experience in investigative preclinical and clinical research interacting with a network of clinical, pharmaceutical, government, and basic researchers in the US and Europe. In 2000, Dr. Lori was recognized as a “Hero in Medicine” for his achievements in HIV therapy and co-authored over 100 publications.
Dr. Sti Forstenlehner
Business Development
Dr. Forstenlehner has more than 30 years of experience in the Pharma and Biotech-Industry. He set-up the Gilead Sciences affiliate in Austria as the first of the so-called smaller markets in the EU. Further experience he gained in the Plasmaprotein/Rare Diseases area and with AI improved post-processing software in radiology.
Dr. Oliver Wüseke
Advisor - Business Strategy & Fundraising
Oliver Wüseke is a life science entrepreneur who held key leadership roles at Herophilus and Mantra Bio, two US-based biotech Startups. He is an experienced biotech operator and fundraiser who has scaled companies, built high-performing teams, and shaped scientific and business strategies to attract substantial venture capital investments.
Andras G. Szasz
Software Architect
Mr. Szasz is a computer scientist and data scientist specializing in AI-driven vaccine design. At VERDI Solutions, he develops and automates personalized and off-the-shelf cancer vaccine design pipelines, focusing on patient-specific peptide selection based on predicted immunogenicity and safety.
Tamas Kos
Bionics Engineer
Mr. Kos is a bioinformatician specializing in sequencing data analysis and a doctoral researcher at Semmelweis University, Budapest. At VERDI Solutions, his responsibilities include the identification of tumor-associated targets, bioinformatics database development, and integrative data analysis. Previously, he has been involved in projects focused on translational cancer research.
Abris Heisz
Software Engineer
Mr. Heisz is a computer scientist specializing in bioinformatics pipeline automation and RNA sequencing analysis for cancer immunotherapy. At VERDI Solutions, he designs and deploys scalable, cloud-based workflows for tumor sample analysis, variant calling, and target discovery, integrating biological immunotherapy models for personalized peptide vaccine development.